Announcement
OpenEvidence adds MSK's OncoKB to its platform for US oncologists
OpenEvidence says over 85% of oncologists at Memorial Sloan Kettering Cancer Center use its platform.
TLDR
OpenEvidence says it and Memorial Sloan Kettering Cancer Center have built OncoKB, MSK's expert interpretation of a tumor's genetics, into the OpenEvidence platform for oncologists across the US. The company says over 85% of oncologists at MSK use OpenEvidence and describes the integration as a way to widen OncoKB's reach.
Combined views
108.1K
2 Sources, first seen ago
